Advanced in Opioid Induced Constipation

Dr. Chih-yi '. Liao

Hematology Oncology | Hematology | Oncology
The University Of Chicago Medical Center
5841 S Maryland Ave, 
Chicago, IL 
Accepting New Patients
Offers Telehealth
Advanced in Opioid Induced Constipation
The University Of Chicago Medical Center
5841 S Maryland Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Chih-yi Liao is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Liao is rated as an Advanced provider by MediFind in the treatment of Opioid Induced Constipation. His top areas of expertise are Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Hepatectomy, and Gastrostomy. Dr. Liao is currently accepting new patients.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
The University Of Chicago Medical Center
Uchicago Medicine Northwest Indiana
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5841 S Maryland Ave, Chicago, IL 60637
Other Locations
THE UNIVERSITY OF CHICAGO
600 Vale Park Rd N, Uchicago Medicine Cancer C, Valparaiso, IN 46383

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Study Phase: Phase 2
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 2
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drug: ZW49
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Enrollment Status: Terminated
Publish Date: June 13, 2024
Intervention Type: Drug
Study Drug: TPX-0046
Study Phase: Phase 1/Phase 2
Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Enrollment Status: Withdrawn
Publish Date: August 16, 2018
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 1
View 6 Less Clinical Trials

35 Total Publications

Evaluating the role of postoperative long-acting somatostatin analog therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking.
Evaluating the role of postoperative long-acting somatostatin analog therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking.
Journal: Surgery
Published: March 07, 2025
Similar Doctors
Advanced in Opioid Induced Constipation
Dr. Neel Shah
Hematology | Oncology
Advanced in Opioid Induced Constipation
Dr. Neel Shah
Hematology | Oncology

Northwest Cancer Centers PC

1001 Calumet Ave, 
Dyer, IN 
 (19.7 miles away)
812-220-4476
Languages Spoken:
English
See accepted insurances

Neel Shah is a Hematologist and an Oncologist in Dyer, Indiana. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Opioid Induced Constipation. His top areas of expertise are Agranulocytosis, Chronic Familial Neutropenia, Familial Colorectal Cancer, and Colorectal Cancer.

Experienced in Opioid Induced Constipation
Dr. Rozina A. Chowdhery
Hematology | Oncology
Experienced in Opioid Induced Constipation
Dr. Rozina A. Chowdhery
Hematology | Oncology
4445 W Irving Park Rd Ste 400, 
Chicago, IL 
 (13.1 miles away)
630-790-1555
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rozina Chowdhery is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Chowdhery has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Opioid Induced Constipation. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Breast Cancer, and Paget Disease of the Breast.

Experienced in Opioid Induced Constipation
Dr. Jeffrey C. Cilley
Hematology Oncology | Oncology | Hematology
Experienced in Opioid Induced Constipation
Dr. Jeffrey C. Cilley
Hematology Oncology | Oncology | Hematology

Endeavor Health Medical Group

5140 N California Ave, 
Chicago, IL 
 (13.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Cilley is a Hematologist Oncology specialist and an Oncologist in Chicago, Illinois. Dr. Cilley is rated as a Distinguished provider by MediFind in the treatment of Opioid Induced Constipation. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Cilley is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Liao's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile